INS and Obesity: Increased expression and activation of GSK-3 have been observed in the skeletal muscle of rodent models of obesity and obese individuals with type 2 diabetes, and this dysregulation is associated with impaired insulin-mediated glucose disposal and glycogen synthase activation [65].